194 related articles for article (PubMed ID: 21544687)
1. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.
van Beers MM; Sauerborn M; Gilli F; Brinks V; Schellekens H; Jiskoot W
Pharm Res; 2011 Oct; 28(10):2393-402. PubMed ID: 21544687
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates.
Abdolvahab MH; Fazeli A; Halim A; Sediq AS; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Apr; 36(4):247-57. PubMed ID: 26835734
[TBL] [Abstract][Full Text] [Related]
3. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.
van Beers MM; Sauerborn M; Gilli F; Brinks V; Schellekens H; Jiskoot W
Pharm Res; 2010 Sep; 27(9):1812-24. PubMed ID: 20499141
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.
Van Beers MM; Gilli F; Schellekens H; Randolph TW; Jiskoot W
J Pharm Sci; 2012 Jan; 101(1):187-99. PubMed ID: 21918983
[TBL] [Abstract][Full Text] [Related]
5. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.
Hermeling S; Aranha L; Damen JM; Slijper M; Schellekens H; Crommelin DJ; Jiskoot W
Pharm Res; 2005 Dec; 22(12):1997-2006. PubMed ID: 16184451
[TBL] [Abstract][Full Text] [Related]
7. Development of a transgenic mouse model immune tolerant for human interferon Beta.
Hermeling S; Jiskoot W; Crommelin D; Bornaes C; Schellekens H
Pharm Res; 2005 Jun; 22(6):847-51. PubMed ID: 15948027
[TBL] [Abstract][Full Text] [Related]
8. Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants.
Kijanka G; Sauerborn M; Boon L; Schellekens H; Brinks V
J Pharm Sci; 2015 Feb; 104(2):396-406. PubMed ID: 25219665
[TBL] [Abstract][Full Text] [Related]
9. A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta.
Abdolvahab MH; Brinks V; Schellekens H
J Immunol Methods; 2014 Dec; 415():17-23. PubMed ID: 25450255
[TBL] [Abstract][Full Text] [Related]
10. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.
Hermeling S; Schellekens H; Maas C; Gebbink MF; Crommelin DJ; Jiskoot W
J Pharm Sci; 2006 May; 95(5):1084-96. PubMed ID: 16552750
[TBL] [Abstract][Full Text] [Related]
11. Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.
Sauerborn M; van Beers MM; Jiskoot W; Kijanka GM; Boon L; Schellekens H; Brinks V
J Clin Immunol; 2013 Jan; 33(1):255-63. PubMed ID: 22945588
[TBL] [Abstract][Full Text] [Related]
12. Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.
Torosantucci R; Sharov VS; van Beers M; Brinks V; Schöneich C; Jiskoot W
Mol Pharm; 2013 Jun; 10(6):2311-22. PubMed ID: 23534382
[TBL] [Abstract][Full Text] [Related]
13. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.
Barnard JG; Babcock K; Carpenter JF
J Pharm Sci; 2013 Mar; 102(3):915-28. PubMed ID: 23233295
[TBL] [Abstract][Full Text] [Related]
14. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.
Torosantucci R; Brinks V; Kijanka G; Halim LA; Sauerborn M; Schellekens H; Jiskoot W
J Pharm Sci; 2014 May; 103(5):1367-74. PubMed ID: 24619587
[TBL] [Abstract][Full Text] [Related]
15. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
van Beers MM; Jiskoot W; Schellekens H
J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).
Runkel L; Meier W; Pepinsky RB; Karpusas M; Whitty A; Kimball K; Brickelmaier M; Muldowney C; Jones W; Goelz SE
Pharm Res; 1998 Apr; 15(4):641-9. PubMed ID: 9587963
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
19. n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity.
Rifkin RA; Maggio ET; Dike S; Kerr DA; Levy M
J Neuroimmune Pharmacol; 2011 Mar; 6(1):158-62. PubMed ID: 20532646
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.
Filipe V; Jiskoot W; Basmeleh AH; Halim A; Schellekens H; Brinks V
MAbs; 2012; 4(6):740-52. PubMed ID: 22951518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
